Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q7Z624

UPID:
CMKMT_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q7Z624; Q4ZG15; Q53SS6; Q8N6P5; Q9H5G8

BACKGROUND:
Calmodulin-lysine N-methyltransferase, with its recommended name and unique enzymatic function, catalyzes the trimethylation of 'Lys-116' in calmodulin, a process essential for the modulation of calcium-mediated signaling. This enzyme's activity underscores its importance in cellular homeostasis and signal transduction.

THERAPEUTIC SIGNIFICANCE:
Linked to the pathogenesis of Hypotonia-cystinuria syndrome, Calmodulin-lysine N-methyltransferase's dysfunction highlights its potential as a therapeutic target. Exploring its biological mechanisms further could lead to innovative treatments for diseases characterized by metabolic and signaling abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.